论文部分内容阅读
为研究ｒａｓ、ＨＥＲ－２／ｎｅｕ癌基因的表达与子宫内膜癌发生、发展的关系，本文用免疫组化ＡＢＣ法检测了２３例正常子宫内膜、４４例子宫内膜增殖症及１０３例子宫内膜癌组织中ｒａｓ、ＨＥＲ－２／ｎｅｕ癌基因的表达情况。结果表明：在子宫内膜非典型增生中即存在ｒａｓ基因的过度表达，过度表达率为２０％，子宫内膜癌ｒａｓ的过度表达率为１８．４％，且ｒａｓ的过度表达与子宫内膜癌的病理分级、分期及患者的生存率无关，说明ｒａｓ癌基因的异常表达可能与癌形成的早期有关。子宫内膜癌中ＨＥＲ－２／ｎｅｕ的过度表达率为２７．２％，ＨＥＲ－２／ｎｅｕ的过度表达与子宫内膜癌的分期无关，与分级及患者的预后有关，存在ＨＥＲ－２／ｎｅｕ过度表达者的生存率低于无过度表达者，前者的５年生存率为５４．８％，后者为７９．６％，结果提示ＨＥＲ－２／ｎｅｕ的过度表达是判断子宫内膜癌预后的生物学指标。
To study the relationship between the expression of ras and HER-2/neu oncogene and endometrial carcinogenesis, we used immunohistochemical ABC method to detect 23 cases of normal endometrium, 44 cases of endometrial hyperplasia and 103 cases of endometrial hyperplasia. The expression of ras and HER-2/neu oncogenes in endometrial cancer tissues. The results showed that overexpression of ras gene was found in endometrial atypical hyperplasia, the overexpression rate was 20%, the overexpression rate of endometrial carcinoma ras was 18.4%, and ras overexpression was associated with endometrium. The pathological grading, staging, and survival rate of patients were not related to cancer, suggesting that the abnormal expression of ras oncogene may be related to the early stage of cancer formation. The overexpression rate of HER-2/neu in endometrial cancer was 27.2%. Overexpression of HER-2/neu was not associated with the stage of endometrial cancer. It was related to the grade and prognosis of patients. HER-2/HER-2/ The survival rate of patients with neu overexpression was lower than that without overexpression. The former had a 5-year survival rate of 54.8%, and the latter was 79.6%. The results suggest that HER-2/neu overexpression is a marker for endometrial cancer. The biological indicators of prognosis.